Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab
BackgroundCamrelizumab, a programmed death 1 (PD-1) inhibiting antibody, has demonstrated efficacy in various malignancies and received approval in multiple countries. Despite its therapeutic benefits, camrelizumab is associated with a unique spectrum …